Daraxonrasib in Canada: New Phone Line Reaches Health Ministers
Daraxonrasib is approved in the United States and Europe. In Canada, its maker has not applied, and no one can tell patients when it will.
FOR IMMEDIATE RELEASE
Daraxonrasib is approved in the United States and Europe. In Canada, its maker has not applied, and no one can tell patients when it will.
MOUNT PEARL, NEWFOUNDLAND AND LABRADOR, CANADA, November 19, 2026. Today, on World Pancreatic Cancer Day, The Heather Cutler Foundation and Pancreatic Cancer Can't Wait announce plans to open a toll-free line on Monday that puts Canadians straight through to the office of the federal Minister of Health or their provincial health minister. Callers are asked to deliver one short message: name someone to lead on Canadian access to daraxonrasib, and tell patients what happens next.
“Diplomacy with drug manufacturers is a luxury that patients with terminal illnesses don't have,” said Christopher Cutler, founder and executive director of The Heather Cutler Foundation. “We believe in constructive dialogue. But dialogue cannot become an excuse for indefinite delays, unanswered questions or inaction. For patients facing a terminal diagnosis, time is not an administrative consideration. It is something they are running out of.”
Approved elsewhere, not filed in Canada
Daraxonrasib, sold as Rasonque, was approved by the U.S. Food and Drug Administration on August 26, 2026 for certain adults with metastatic pancreatic cancer. In the trial behind that approval, median overall survival was 13.2 months for people who took the drug and 6.7 months for people on standard chemotherapy. On November 16, 2026, its maker, Revolution Medicines, announced approval by the European Commission.
In Canada, the process has not started. Revolution Medicines told the Foundation on November 5, 2026 that it has not filed with Health Canada and has no filing date to share. Until it files, Health Canada has nothing to review. Once it does, the review target is 300 days, or 180 days under priority review, and each province then decides whether its public plan will pay.
In the meantime, Canadian patients have few options:
- Clinical trial sites in Canada are limited.
- The company describes a paid access route for patients outside the United States, but has not said what a Canadian would be charged. The U.S. list price is US$39,800 for a 30-day supply.
- No government, federal or provincial, has told patients who is responsible for getting an answer. Canadians are starting to entertain travel to the US in order to apply for patient funding assistance with a US residential address
Where you live already decides your care
The delay lands on a system the Foundation has already measured. Its October 2026 report card, Where You Live Matters, assessed how all 13 provinces and territories respond to pancreatic cancer. None runs a dedicated pancreatic cancer program. Of $23.3 million in federal pancreatic cancer research funding, about one per cent reached Atlantic Canada. Newfoundland and Labrador received a C.
The Foundation is named for Heather Cutler, a registered nurse who served Newfoundland and Labrador for more than 35 years. She was diagnosed with pancreatic cancer in 2022, at 60. She could not get into a clinical trial, and a drug Health Canada had already approved was not covered for her.
“My mother was a nurse. She knew exactly what to ask, and she still could not get an answer,” Cutler said. “Now eight or nine families write to us every week asking how to get this drug, and we cannot tell them when, how or at what cost. Canadians are at a standstill, and families are left to find their own way through. We cannot sit by and wait.”
One number, two minutes
The line opens Monday, November 23. Anyone in Canada can call (855) 754-5045 and press 1. The line will connect them to the federal Minister of Health's office or to the health minister's office in any of the ten provinces. Customized script generated on the campaign page, and people who would rather write can do that instead. The Foundation does not record or listen to the calls. It will publish every written reply it receives from a minister's office, with its date.
The Foundation is also inviting patients, caregivers and families to share their story and how this delay is affecting them. After their call, people can record a short message, up to two minutes, about why they are taking part. With each person's permission, those messages are shared on the campaign page as audio clips, alongside patient impact videos.
Earlier this week, the Foundation wrote to the offices of the federal Minister of Health and of every provincial and territorial health minister to notify them ahead of the public launch.
Two campaigns, one call
The campaign is an equal partnership between The Heather Cutler Foundation and Pancreatic Cancer Can't Wait, the patient-led campaign started by Salman Syed. Syed is a husband and father of two in Ontario who is living with metastatic pancreatic cancer.
“I'm fighting for affordable access, for myself and for every Canadian who needs it,” Syed says on his campaign's website. Cutler and Syed built the campaign together. Pancreatic Cancer Can't Wait brings the voices of patients and families who are living this now, and the Foundation's phone line carries them to ministers' offices.
Together, the two organizations are asking three things: that the federal Minister of Health name a lead on Canadian access to daraxonrasib, that provincial and territorial health ministers name a lead and say whether interim or exceptional funding could be considered for eligible patients, and that Revolution Medicines apply to Health Canada and publish a clear access route for Canadian patients.
Lines open Monday, November 23: call (855) 754-5045, press 1. Scripts and details: https://heathercutler.ca/daraxonrasib/
About The Heather Cutler Foundation
The Heather Cutler Foundation is a registered Canadian charity (743014227 RR 0001) based in Mount Pearl, Newfoundland and Labrador. Founded by Christopher Cutler in memory of his mother, Heather Cutler, RN, it works on pancreatic cancer education, patient support and advocacy, with a focus on people outside Canada's large urban centres.
About Pancreatic Cancer Can't Wait
Pancreatic Cancer Can't Wait is a patient-led campaign started by Salman Syed of Ontario, who is living with metastatic pancreatic cancer. It calls for affordable access to Rasonque for every Canadian who needs it, including a compassionate or cost-shared supply program from the manufacturer and exceptional-access funding from the provinces. It says hundreds of patients, caregivers, health professionals and advocates across Canada have added their voice. The campaign is independent of Revolution Medicines and Health Canada. More at pancreaticcantwait.ca.
Media contact: Christopher Cutler, (855) 754-5045, press 2, press@heathercutler.ca
Sources: U.S. Food and Drug Administration, August 26, 2026 (approval and trial results). Revolution Medicines, November 16, 2026 (European Commission approval). Revolution Medicines responds, The Heather Cutler Foundation, November 5, 2026 (filing status, access route and U.S. price). Health Canada review performance targets. Where You Live Matters, The Heather Cutler Foundation, October 2026.